Nonprofit, nonpartisan journalism. Supported by readers.


Severe blood loss treatment revived, headed for trials in 2012

Colorado drugmaker Ariel Pharmaceuticals has scooped up some discarded University of Minnesota technology treating severe blood loss. Ariel hopes to have the drug to the military as early as 2016, and into the general consumer market two years later.

The drug therapy Tamiasyn was developed at the University of Minnesota, which initially transferred the treatment to a local startup, VitalMedix. VitalMedix declared bankruptcy in early 2010 when it couldn’t raise money for trials and returned the Tamiasyn license to the school.

The drug treats hemorrhagic shock victims who have lost significant amounts of blood and could also help avoid organ damage in these patients. Arial expects the drug to be used heavily by the military, emergency workers and anyone else who first treats shock victims.

University officials called Ariel a “good fit because it focuses on the development and commercialization of trauma products.”

Ariel President Steve Orndorff stated his company will begin preclinical studies with hopes of submitting an IND application to the U.S. Food and Drug Administration in the summer of 2012. Phase I studies would hopefully begin by the end of that year.

The commercialization process will take four to six years for the military and six to eight years for civilian patients, Orndorff stated.

Deanna Pogorelc contributed to this report.

You can also learn about all our free newsletter options.

No comments yet

Leave a Reply